Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31228757 | 0.98 | KDM1A (0.60) | NPC1RAB9AGFERKDM1ARCOR1 | |
| SCHEMBL29368677 | 0.85 | NPC1 (0.60) | NPC1RAB9AGFERKDM1ARCOR1 | |
| SCHEMBL6037543 | 0.84 | KDM4E (0.60) | NPC1RAB9AGFERKDM1ARCOR1 | |
| SCHEMBL22822554 | 0.84 | RAB9A (0.58) | NPC1RAB9AGFERKDM1ARCOR1 | |
| SCHEMBL16692690 | 0.84 | NPC1 (0.58) | NPC1RAB9AGFERKDM1ARCOR1 | |
| SCHEMBL7589089 | 0.84 | KDM1A (0.61) | NPC1RAB9AGFERKDM1ARCOR1 | |
| SCHEMBL6037540 | 0.84 | NPC1 (0.58) | NPC1RAB9AGFERKDM1ARCOR1 | |
| Ethoxycarbonyl Group SCHEMBL28270717 | 0.83 | NPC1 (0.45) | NPC1RAB9AGFERKDM1ARCOR1 | |
| SCHEMBL12764052 | 0.80 | MEN1 (0.59) | NPC1RAB9ASMN1; SMN2TP53TMIGD3 | |
| SCHEMBL31265765 | 0.80 | NPC1 (0.64) | NPC1RAB9AGFERTP53ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761542-A2 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | claimed |
| WO-2005121145-A2 | OCTAHYDRO-PYRROLO[3,4-C] DERIVATIVES AND THEIR USE AS ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | WO | claimed |
| CN-120483964-A | Chimeric derivative for targeted degradation of N-phenylpyrrole formamide protein and application thereof | 贵州医科大学 | 2025-08-15 | — | — | CN | disclosed |
| CN-120483964-A | Chimeric derivative for targeted degradation of N-phenylpyrrole formamide protein and application thereof | 贵州医科大学 | 2025-08-15 | — | — | CN | disclosed |
| CN-119330867-A | Pyrrole amide derivative, preparation method thereof and beta-type pyrrole amide derivative2Use of allosteric antagonists of adrenergic receptors | 常州大学 | 2025-01-21 | — | — | CN | disclosed |
| US-20250002455-A1 | NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY | UNIV LJUBLJANI (SI) | 2025-01-02 | — | — | US | disclosed |
| EP-4263503-A1 | NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY | Univerza V Ljubljani (SI) | 2023-10-25 | — | — | EP | disclosed |
| US-11571409-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| CN-109475521-B | Anti-proprotein convertase subtilisin Kexin type 9 (anti-PCSK 9) compounds and methods of use thereof for treating and/or preventing cardiovascular diseases | 实发生物医学公司 | 2022-11-15 | — | — | CN | disclosed |
| WO-2022129327-A1 | NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY | UNIVERZA V LJUBLJANI (SI) | 2022-06-23 | — | — | WO | disclosed |
| US-20210340126-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-11-04 | — | — | US | disclosed |
| EP-0825193-A1 | Certain fused pyrrolecarboxanilides; a new class of gaba brain receptor ligands | NEUROGEN CORPORATION (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1997034870-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1997-09-25 | — | — | WO | disclosed |
| US-5608079-A | MEMORY ENHANCEMENT IN BRAINS | NEUROGEN CORPORATION (US) | 1997-03-04 | — | — | US | disclosed |
| US-5608079-A | MEMORY ENHANCEMENT IN BRAINS | NEUROGEN CORPORATION (US) | 1997-03-04 | — | — | US | disclosed |
| CN-1143953-A | Certain fused pyrrolecarboxanilides, new class of gaba brain receptor ligands | NEUROGEN CORP (US) | 1997-02-26 | — | — | CN | disclosed |
| EP-0725775-A1 | CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1996-08-14 | — | — | EP | disclosed |
| US-5484944-A | ANXIETY, SLEEP, MEMORY | NEUROGEN CORPORATION (US) | 1996-01-16 | — | — | US | disclosed |
| US-5484944-A | ANXIETY, SLEEP, MEMORY | NEUROGEN CORPORATION (US) | 1996-01-16 | — | — | US | disclosed |
| WO-1995011885-A1 | CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002455-A1 | NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY | TOP1, TOP2A, TOP2B | NPC1 4238/4885RAB9A 4180/4885GFER 3584/4885 |
| US-20210340126-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | NPC1 732/4885RAB9A 2261/4885GFER 4017/4885 |
| US-11571409-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | NPC1 732/4885RAB9A 2261/4885GFER 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.